HP (High Potency) APIs Global Market Report 2024

The hp (high potency) apis market size has grown strongly in recent years. It will grow from $23.39 billion in 2023 to $25.5 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the historical period can be ascribed to a heightened demand for oncology therapies, a growing focus of pharmaceutical companies on the production of high-potency active pharmaceutical ingredients (HPAPIs), an upsurge in healthcare awareness and expenditure, robust economic growth in emerging markets, and a rise in government initiatives.

The hp (high potency) apis market size is expected to see strong growth in the next few years. It will grow to $36.38 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be linked to an increase in the number of cancer cases, a heightened emphasis on precision medicine, and the continuous growth of the ageing population, all contributing to driving the expansion. Major trends expected in the forecast period involve a strategic emphasis on activities such as expanding production facilities and engaging in mergers and acquisitions, a dedicated focus on augmenting investments to bolster HPAPI production, the incorporation of artificial intelligence (AI) in manufacturing APIs, an emphasis on environmentally sustainable manufacturing practices, and a concentration on launching new, innovative products.

The growth of the HP (high potency) APIs market is driven by the increasing number of cancer cases and the concurrent rise in sales of cancer drugs. The surge in cancer incidence is leading to heightened research and development efforts for anticancer drugs, consequently fueling the demand for the market. According to the International Agency for Research on Cancer (IARC) report by the World Health Organization, the global cancer burden is anticipated to witness an increase of 29.5 million new cases and 16.4 million deaths by 2040. Notably, 70% of cancer-related deaths occur in middle and low-income countries. As a result, the escalating prevalence of cancer is expected to boost revenues for the HP (high potency) APIs market.

Government initiatives aimed at enhancing cancer care and treatment are poised to drive the future growth of the HP (high potency) APIs market. These initiatives encompass policies, funding, and programs implemented by governments to enhance the accessibility, affordability, and quality of care for individuals diagnosed with cancer. The importance of High Potency (HP) APIs in cancer treatment lies in their ability to target specific molecular pathways, thereby enhancing the effectiveness of therapies. An example is the revival of the Cancer Moonshot Initiative unveiled by President Biden in September 2023. The initiative, supported by the Centers for Disease Control and Prevention (CDC), aims to halve the cancer death rate within 25 years and provide comprehensive support to cancer survivors and their families. Consequently, government initiatives to improve cancer care and treatment are propelling the growth of the HP (high potency) APIs market.

Companies operating in the HP (high potency) APIs market are adopting strategies such as expanding production facilities and engaging in mergers and acquisitions to maintain their competitive positions. In June 2022, MilliporeSigma, a global life science business based in the US, inaugurated a $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with a specific focus on cancer treatments.

Major players in the HP (high potency) APIs market are actively pursuing strategic partnerships to drive market revenues. Collaborations offer various advantages, including access to new technology, expanded customer choice, global servicing capabilities, a collaborative global platform, and integrated services. In March 2023, CatSci Ltd., a UK-based provider of innovative process research and development services, partnered with AGC Pharma Chemicals Europe S.L.U. This collaboration enables customers to access a broad range of manufacturing technologies, including fluorination and bromination. It also facilitates AGC Pharma Chemicals' customers to benefit from expertise in state-of-the-art chemical development and analytical development.

In December 2021, SK Capital Partners, a US-based private investment firm, acquired a majority shareholding in SEQENS for an undisclosed amount. This strategic move positions SEQENS as a more potent and concentrated participant in the international markets for specialized ingredients and pharmaceutical solutions. Wavelength Pharmaceuticals, an existing SK Capital portfolio business that is a global manufacturer and developer of active medicinal ingredients, engaged in a combination concurrent with the acquisition. SEQENS, a France-based developer and manufacturer of custom High-Potency APIs, is a key player in this transformative development.

Major companies operating in the hp (high potency) apis market report are Merck KGaA, Pfizer, Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals, Lonza Group AG, Sanofi (EUROAPI), Corden Pharma International, Dr. Reddy’s Laboratories Ltd., Siegfried Holding AG, Novartis, Roche India, Arlak Biotech (India), Healthkind Labs Pvt. Ltd., Swisschem Healthcare Pvt. Ltd., Apikos Pharma, Kolaz Biotech, Cstone Pharma (China), Carsgen Therapeutics (China), Jw Therapeutics (China), Beigene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Otsuka Pharmaceutical Co, Ltd (Japan), Legend Biotech Co (China), Abbott Laboratories, Vectura Group (U.K), Corex Logistics, Dokumeds, Medpace, Labcorp, Almedis (Russia), Neuca, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, Tzmo, Eli Lilly And Company, Bristol-Myers Squibb Company, Apotex, Gilead Sciences, Abbvie Inc., Hisun Usa Inc., Glaxosmithkline, Amega Biotech, Biomarin Pharmaceutical, Ferring Pharmaceuticals, Tikun Olam Cannbit, Wavelength Pharmaceuticals, Saudibio, Tabuk Pharmaceuticals, Cipla, Bayer, Adcock Ingram, Johnson & Johnson, Astrazeneca Pharmaceutical (Pty) Ltd., Eurolab, Ranbaxy (Sa) (Pty) Ltd.

North America was the largest region in the global HP (high potency) APIs market in 2023. Middle East is expected to be the fastest growing region in the HP (high potency) APIs market report during the forecast period. The regions covered in the hp (high potency) apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hp (high potency) apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary categories within the high-potency APIs market are innovative HPAPI and generic HPAPI. Various synthesis types, including synthetic HPAPI and biotech HPAPI, find application in therapeutic areas such as oncology, hormonal disorders, glaucoma, and other medical fields such as respiratory disorders, cardiovascular disease (CVD), diabetes, cosmetology, and erectile dysfunction. Glaucoma comprises a group of eye diseases affecting the optic nerve, crucial for maintaining good vision.

The HP (high potency) APIs market research report is one of a series of new reports that provides HP (high potency) APIs market statistics, including HP (high potency) APIs industry global market size, regional shares, competitors with an HP (high potency) APIs market share, detailed HP (high potency) APIs market segments, market trends and opportunities, and any further data you may need to thrive in the HP (high potency) APIs industry. This HP (high potency) APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market consists of sales of cytotoxic compounds and sex hormones. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.